Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Int J Tuberc Lung Dis. 2012;16(3):364-9. doi: 10.5588/ijtld.11.0511.
Confirmation of cure for multidrug-resistant tuberculosis (MDR-TB) patients requires laboratory tests for Mycobacterium tuberculosis growth on culture media. Outcome decisions dictate patient management, and inaccuracies place patients at an increased risk of morbidity and mortality, and may contribute to continued transmission of MDR-TB.
To examine concordance between programmatic and laboratory-based MDR-TB treatment outcomes.
The study population included 1658 MDR-TB patients in Peru treated between 1996 and 2002 with both program and laboratory-based outcomes. Laboratory-based outcomes were assigned according to international standards requiring at least five consecutive negative cultures in the last 12 months of treatment to confirm cure.
Compared to the global culture-defined standard classification, only 1.1% of treatment successes, but 54.3% of failures, were misclassified programmatically. Overall, 10.4% of patients identified by a clinician as having a successful treatment outcome still had cultures positive for MDR-TB.
Most patients with successful treatment outcomes by strict culture definitions were also classified by clinicians as having successful outcomes. However, many culture-confirmed failures were missed. In light of delays and incomplete access to culture in MDR-TB programs, efforts should be made to improve the accuracy of programmatically determined treatment outcomes.
耐多药结核病(MDR-TB)患者的治愈确认需要在培养基上进行结核分枝杆菌生长的实验室检测。治疗结局决定了患者的管理方案,而检测结果不准确会使患者面临更高的发病率和死亡率风险,并可能导致 MDR-TB 的持续传播。
研究基于方案和基于实验室的 MDR-TB 治疗结局之间的一致性。
该研究人群包括 1996 年至 2002 年期间在秘鲁接受治疗的 1658 例 MDR-TB 患者,这些患者同时具有基于方案和基于实验室的治疗结局。基于实验室的治疗结局根据国际标准进行分配,要求在治疗的最后 12 个月内至少连续 5 次培养物阴性才能确认治愈。
与全球基于培养物的标准分类相比,仅 1.1%的治疗成功病例被错误地归类为方案成功,而 54.3%的治疗失败病例被错误地归类为方案失败。总体而言,10.4%的临床医生认为治疗结局成功的患者,其培养物仍为 MDR-TB 阳性。
根据严格的培养物定义,大多数治疗结局成功的患者也被临床医生归类为治疗成功。然而,许多经培养物确认的失败病例被遗漏了。鉴于 MDR-TB 项目中存在延迟和不完全获得培养物的情况,应努力提高方案确定的治疗结局的准确性。